Igor Tsaur, Director and Chairman, Department of Urology at University Hospital Tübingen, shared a post on LinkedIn:
“Tübingen Launches First Site for the DEPECA-1 Trial!
I am thrilled to announce that the Department of Urology, Tübingen University Hospital, was initiated yesterday as the first study site for our national multicenter, Tuebingen-led, Investigator-Initiated Trial (IIT), DEPECA-1.
This landmark achievement signals a spark of hope for patients with penile cancer, who will be treated with the promising drug combination of enfortumab vedotin and avelumab in the first-line setting of surgically incurable locally advanced or metastatic disease.
Our sincere gratitude goes to the entire medical and administrative staff of our department, the trial sponsor IKF – The Frankfurt Institute of Clinical Cancer Research, our funders Merck Group and Astellas Pharma, and all other supporting parties who contributed to this important launch.
We look forward to commencing patient recruitment soon!.”
More posts featuring Igor Tsaur.